Related by context. All words. (Click for frequent words.) 59 IIa clinical 57 Bayer HealthCare Onyx Pharmaceuticals 55 Testosterone MDTS R 55 confirmatory pivotal 55 REVIVE Diabetes 55 Testosterone MDTS ® 54 multicenter Phase 54 CG# oncolytic virus 54 randomized controlled multicenter 54 EXPLORE Xa 54 LymphoStat B Phase 53 multicenter dose escalation 53 SISP 53 recombinant PSMA vaccine 53 randomized discontinuation 53 Scopus Affiliation Identifier 53 designated HVTN 53 selectin antagonist 53 Initiated Phase 52 Evaluation Program CTEP 52 initiate multicenter 52 TELINTRA R 52 dependent kinase inhibitor 52 VICTOR E1 52 Second Pivotal Phase 52 clinic automation LabPas 52 IIb clinical trial 52 ALISTA TM 52 BRIM2 52 ORAL Solo 52 NABTT 52 multicenter phase 51 Population Enumeration 51 label multicenter Phase 51 LUX Lung 51 systemic Phase 1b 51 Phase Ib clinical trials 51 Accelerated Feasibility Study 51 Phase1 51 Gentamicin Surgical Implant 51 Phase 1b clinical trials 51 Confirmatory Phase 51 European Sepsis Trial 51 label dose escalation 51 Phase III multicenter 50 SCHOOL Session 50 Urocidin ™ 50 randomized controlled Phase 50 Phase 50 Luramist TM 50 label multicenter randomized 50 Albuferon Phase 50 RESTORE CLI trial 50 blinded randomized placebo controlled 50 IIa clinical trials 50 AZX# Phase 50 Initiate Phase 50 multicenter Phase II 50 IMPACT DCM clinical 50 bapineuzumab AAB 50 GATTEX ® 50 registrational Phase 50 Plaza Sentral 50 VEGFR2 inhibitor 50 phase Ib 49 label multicenter 49 Phase 1a 49 Phase Ib II 49 Schematic Design 49 phase IIa 49 evaluating tesamorelin 49 Phase 2a clinical trials 49 Phase Ib clinical 49 NO# [002] 49 · Oversee 49 BLOOM Behavioral modification 49 PROTECT AF 49 JZP 49 Randomized Phase II 49 · Coordinate 49 Phase III TRIST 49 phase Ib clinical 49 ACCLAIM COPD 49 OLpur TM H2H 49 Orosi Mill project 48 SUCCEED trial 48 evaluating satraplatin 48 Thur. Sat 48 PRECISE Trial 48 adecatumumab MT# 48 Chidliak exploration 48 flagship Yenipazar polymetallic VMS 48 STEALTH C 48 treatment naive genotype 48 Phase 1b Clinical Trial 48 Acetavance TM intravenous acetaminophen 48 imetelstat GRN#L 48 Mirbat Beach 48 Phase IIa proof 48 controlled multicenter Phase 48 Randomized phase 48 Huaiyin Power Plant 48 XL# XL# XL# 48 BRIM3 48 placebo controlled Phase 48 Biopharmaceuticals AG 48 Phase Ib IIa 48 dose escalation clinical 48 ADMIRE HF 48 Sorafenib HCC Assessment 48 blinded randomized 48 IMC #B 48 transmucosal delivery system 48 TMC# C# 48 ALN VSP Phase 48 Phase II 48 controlled multicenter 48 alvespimycin 47 VALOR trial 47 pivotal bioequivalence 47 Anchors Aweigh wrap 47 BOLC 47 MagEnergy 47 Truvada tablets 47 lock loop PLL 47 ABSORB clinical 47 mutually satisfactory definitive 47 Clabber Creek 47 lead Aganocide compound 47 MEND CABG 47 ENDEAVOR IV 47 Libby adit 47 SYMMETRY trial 47 LUMINATE 47 Innovative Partnerships Program 47 PSMA ADC 47 STP McKay Thermal 47 overactive bladder AA# 47 Contrast Echocardiography 47 Phase #b/#a clinical 47 BiTE R 47 initiated Phase Ib 47 immunosuppressive compound 47 initiate multicenter Phase 47 Syncria albiglutide 47 ACCLAIM II 47 phase IIa clinical 47 lorcaserin Phase 47 PrevOnco ™ 47 3 registrational trial 47 II SBIR 47 Lockerby Depth 47 mediations arbitrations 46 ACCEDE 46 Randomized Phase 46 ENDEAVOR IV clinical 46 ICESS 46 Phases II 46 Phase 1a clinical 46 Infopark Kochi 46 Downtown Streetscape 46 CHAMPION PCI 46 Phase IIb III 46 hGH CTP Phase 46 drug pipeline TAFA# 46 HCV SPRINT 46 FORTIS M 46 Diagnosis DCTD 46 R#/MEM # 46 Phase 2a proof 46 ENRICH trial 46 palifosfamide Zymafos TM 46 Eniluracil 46 Lock Loop PLL 46 Phase lll 46 Phase Ib 46 comparing alemtuzumab 46 MEND CABG II 46 PROVENGE ® 46 APEX PD 46 treatment naïve genotype 46 PF # [002] 46 CTA# Injection 46 REVIVE TA 46 evaluating carfilzomib 46 CATIE AD 46 multicenter Phase III 46 IMPACT IMmunotherapy 45 shodeo 45 studies evaluating satraplatin 45 IND enabling 45 PREGNANT PROCHIEVE Extending GestatioN 45 multicentre randomized 45 Exherin TM 45 GetGoal Phase III 45 clinical trials Archexin 45 initiated confirmatory Phase 45 PrevOnco 45 Ispinesib SB # 45 dacetuzumab SGN 45 plus Copegus R 45 Pivotal Phase 45 budesonide MMX Phase III 45 confirmatory Phase III 45 ENTB 45 Phase IIb kidney transplant 45 confirmatory Phase 3 45 Phase III Pivotal 45 ADVANCE PD 45 IMPACT DCM 45 TRACON Pharmaceuticals Inc. 45 Phase 2a clinical 45 Block XIX 45 Successfully Completes Phase 45 serine protease inhibitor CU# 45 mGluR5 negative 45 Commences Phase 45 IIa trial 45 Phase III registrational 45 greenfield aluminum smelter 45 Sapacitabine 45 Genasense oblimersen sodium Injection 45 Heap Leach Project 45 CPV Keenan 45 dose escalation phase 45 docetaxel Taxotere R 45 Dose Ranging Study 45 Phase #b/#a 45 dose escalation Phase 45 unique alkylating agent 45 R roscovitine CDK cyclin 45 Aplidin R 45 Oluvil Port 45 GASTRO 45 Phase III VISTA 45 www.forwardair.com beginning 45 Phase IIB 45 AIR CF2 45 evaluating mipomersen 45 PRESEPT 45 intravenous methylnaltrexone 45 confirmatory clinical 45 BiTE antibody MT# 45 Zerenex Phase 45 Gulfport Sportsplex 45 generation HCV protease 45 ongoing Phase 1b 45 phase IIb 45 trastuzumab DM1 T DM1 45 LibiGel Phase III 45 Goldcrest Dreams 45 Transfer BOOT basis 45 thorough QT 45 includes TOLAMBA TM 44 CVx ChannelVision Expo 44 ARRY # 44 6R BH4 tetrahydrobiopterin naturally 44 Phase 1b 44 multicentre randomized double 44 Cloretazine ® 44 Phase IIIb clinical 44 tramiprosate Alzhemed TM 44 multicenter randomized clinical 44 Phase IV 44 Investigational Device Exemption 44 oral picoplatin 44 Luveniq 44 Pivotal Trial 44 ALSYMPCA 44 Phase IIa trials 44 SBIR Phase 44 Phase IIA 44 ZYBRESTAT fosbretabulin 44 GENASIS clinical 44 Multiple Ascending Dose 44 Phase 2b clinical 44 occurring enzyme cofactor 44 registrational trial 44 EQUATE OB 44 multicentre randomized controlled 44 Phase IIIb 44 Special Protocol Assessment 44 Phase Ib Clinical Trial 44 prosecutor Matt Kemmy 44 Phase IIIB 44 COSIRA trial 44 placebo controlled Phase III 44 D#B 44 fosbretabulin 44 phenylalanine hydroxylase PAH 44 TKB# 44 SCIREX Corporation 44 Phase III psoriasis 44 EOquin TM phase 44 petrophysics 44 Ling Ao 44 Multicenter Phase 44 Anturol TM 44 Kibo pronounced KEE' 44 PRE SURGE 44 multicentre phase 44 RECORD1 44 includes Prototype Demonstration 44 ASONEP 44 Forodesine 44 GLP toxicology studies 44 Harry Palmin President 44 rALLy clinical trial 44 Initiates Phase II 44 Proellex TM 44 multicenter randomized Phase 44 phase III ACCLAIM 44 Early Learners 44 Phase III confirmatory 44 DBFOM 44 multicenter randomized 43 Aflibercept 43 Combination REOLYSIN R 43 Chateau Elysee 43 GSM1x 43 REG2 43 Phase III placebo controlled 43 SDD phase 43 Multicenter Randomized 43 dose escalation trial 43 cGMP manufacture 43 Radius Studio 43 Phase 2b Study 43 BioSante LibiGel Phase III 43 Nasdaq SPWRA SPWRB 43 placebo controlled dose escalation 43 Daclizumab 43 Phase III Psoriasis 43 under NHDP Phase 43 IND Investigational New 43 ProCord 43 Curaxin CBLC# 43 Phase Ib study 43 XpandR 43 Trastuzumab DM1 43 Wattenbarger Auditorium 43 Study Evaluating 43 phase IIb clinical 43 Ceflatonin R 43 AVADO 43 EndoBarrier ™ 43 JunJing II 43 CEQ# 43 LUVENIQ 43 UVIDEM 43 Phase 2b clinical trials 43 prospective randomized placebo 43 confirmatory Phase 43 Inspired Gambit 43 ATTAIN 43 HCD# [002] 43 PDX pralatrexate 43 Phase 1b clinical 43 Oral NKTR 43 randomized Phase 2b 43 HEPLISAV ™ 43 XL# SAR# 43 BLA filing 43 PI3K/Akt pathway inhibitor 43 II Clinical Trial 43 Glufosfamide 43 Phase III 43 Phase 2b Clinical Trial 43 Teesta Low 43 Trial Evaluating 43 avanafil PDE5 inhibitor 43 TASQ 43 Completes Patient Enrollment 43 STTR Phase 43 Ostabolin C TM 43 Pivotal Phase II 43 CAMMS# 43 CAPACITY trials 43 non nucleoside HCV 43 PPPAC 43 assessing T DM1 43 HGS ETR1 43 PRECiSE 43 INSPIRE Trial Phase III 43 ARDIS 43 initiate Phase 1b 43 subcutaneous Herceptin 43 pivotal Phase 43 cathepsin K inhibitor 43 Valente Conte 43 Ngezi Phase 43 Biojector R 43 TEMSO 43 evaluating bafetinib 43 MKC# MT 43 Phase 2b 43 Phase III Clinical Trial 43 iscurrently 43 Umeco Composites 43 Sun.Star Cebu Sunnex 42 Phase III pivotal 42 Oregon backcounry earlier 42 NFM celebrated 42 Clinical Trial 42 NHDP Phase III 42 Enobia 42 Submission deadline 42 Dextofisopam Phase 2b 42 metastatic castrate resistant 42 Minera Phelps Dodge 42 dose escalation study 42 RI Prichard 42 home eldercare evaluation 42 austere navigational aids 42 Closes Non Brokered 42 INCB# [001] 42 CCR5 mAb 42 Projected completion 42 Versova Andheri Ghatkopar 42 Agata Nickel Project 42 placebo controlled clinical 42 MIST II 42 Enugu Kaduna 42 FSMP 42 Initiates Phase 42 omacetaxine mepesuccinate 42 randomized Phase III 42 Charles L. Dimmler 42 oral NKTR 42 AIR CF3 42 SAGD Phase 42 Phase #/#a 42 Announce Merger Agreement 42 Ocrelizumab 42 Transfer BOOT 42 Randomised 42 pharmacokinetic PK 42 GSMA IPX 42 ORMD 42 gemcitabine Gemzar ® 42 MSPWorld ™ 42 Medidur TM FA 42 Phase 2a Clinical Trial 42 Phase IIb clinical trials 42 Thorough QT Study 42 SEGIS 42 ELACYT 42 Paulks DE Paulk 42 Opatut Park 42 AKT inhibitor 42 Phase 2b randomized 42 Phase IIb trials 42 registrational 42 TLK# 42 Prostate AdenoCarcinoma Treatment 42 CB2 selective receptor agonist 42 Pivotal Phase III 42 blinded placebo controlled 42 rotary VAD 42 generation PNP inhibitor 42 sched uled 42 double blinded placebo 42 AMPAKINE CX# 42 Phase Ia 42 preclinical toxicology 42 Receives Stockholder Approval 42 mg/m2 cohort 42 Phase III HEAT 42 dextromethorphan quinidine 42 Operational Evaluation 42 Dachan Bay 42 HCV RESPOND 2 42 including eniluracil ADH 42 Rancher Vitalmiro Moura 42 CRMD# 42 bavituximab monotherapy trial 42 carboplatin AUC 6 42 RhuDex 42 Rashidiya Station 42 multiple ascending dose 42 Blind Placebo Controlled Trial 42 Thorough QT 42 Exterior renovations 42 telomerase therapeutic 42 clinical trials Multikine 42 APF# Phase 42 Aranesp Therapy 42 ZYBRESTAT TM 42 Phase IIa clinical 42 HepeX B TM 42 Ling'ao 42 inTaiwan 42 Emerging Pandemic Threats 42 Mtsare Khevi Field 42 multicenter randomized controlled 42 randomized Phase 42 OPT CHF 42 DEB# 42 PANVAC VF 42 oral deforolimus 42 Jegurupadu 42 KERRY O'BRIEN Welcome 42 TUI Mein Schiff 42 CDAD Clostridium difficile 42 PFO migraine 42 memory Ovonic 42 Announces Rescheduling 42 Clinical Trial Evaluating 41 TASKi2 41 huN# DM1 41 CNX GAS CORPORATION 41 HDAC Inhibitor 41 TMC# [002] 41 FOLOTYN ® 41 PROTECTED AREAS 41 past producing Granduc 41 oral opioid modulator 41 initiate Phase IIb 41 resource delineation 41 Pediatric Oncology Branch 41 underground longwall mining 41 LymphoStat B TM 41 strategies TradeMark guides 41 PROACT 41 Preska imposed 41 Completes Enrollment 41 seliciclib CYC# 41 RADIANT 41 Insulspan SIPS 41 Prodarsan R 41 KNS # 41 custirsen 41 multicenter randomized placebo controlled 41 kilometer 2D seismic 41 Randomized Controlled 41 initiate Phase Ib 41 Musheireb project 41 Sapacitabine CYC# cell 41 IIa Clinical Trial 41 sodium thiosulfate STS 41 registrational trials 41 Pequot Lakes Breezy Point 41 NSABP B 41 Pharmos pipeline 41 Zemiva ™ 41 Magampura Port 41 Indibulin 41 Phase IIa Clinical Trial 41 Munda Dam 41 previously unshown video 41 Selective Electrochemical Tumor Ablation 41 NEVO RES 41 Initiates Clinical 41 Phase 2b trial 41 multicenter placebo controlled 41 single ascending dose 41 Phase IIb Clinical Trial 41 ACHIEVE 41 TAXUS ATLAS 41 Quinamed 41 BESST 41 -# dBc Hz [002] 41 Phase IIb clinical 41 JAK1 41 Phase 2b study 41 relapsed refractory multiple myeloma 41 metabolize Phe 41 Sequenom SEQureDx Technology 41 FOLFOX6 chemotherapy regimen 41 #K/#K Run 41 remote unprepared airstrips 41 Kelowna Art Gallery 41 pharmacokinetic PK study 41 hypoxia activated prodrug 41 oral sapacitabine 41 investigational protease inhibitor 41 multicenter randomized double 41 Orbit Validation 41 Archived webcasts 41 Phase 1b trial 41 Orbital Taurus 41 PEARL SC 41 ARISE Phase III 41 Elagolix 41 SystemWeaver 41 generation rotary VAD 41 MYTHOS trial 41 Plicera 41 Mirdiff Hills 41 OncoVEX GM CSF 41 occlusion PAO 41 feasibilty study 41 webseminars 41 Feasibility Study Update 41 MW Parbati 41 recurrent glioma 41 Phase IIb 41 pm www.wallcustance.com 41 double blinded randomized 41 Itibiti Systems 41 metastatic colorectal carcinoma 41 Allovectin 7 41 Zenvia Phase III 41 XIENCE V Stent System 41 MERLIN TIMI 41 ganetespib 41 candidate Liposomal Grb 41 Dose Escalation 41 label dose titration 41 SoftScan ® 41 Pre RELAX AHF 41 satellite constellation Iridium 41 oral calcitonin 41 CTLM ® 41 Subphase 41 randomized discontinuation trial 41 farletuzumab 41 RIBBON 40 Cetrorelix 40 #noon 1pm 40 prospective multicenter 40 MEDWAY Medway 40 catheter occlusion CO 40 Rampura Agucha mine 40 OLpur TM MD 40 Imvamune R 40 Company OTCBB CXDC 40 AACR EORTC NCI 40 MEMEX 40 Matt Treanor bunted 40 Qinshan nuclear 40 IMA# 40 UCoDA 40 Flint knapping 40 Al Furjan 40 Phase 2a 40 randomized multicenter 40 WGS Block 40 randomized #:#:# 40 randomized multicentre 40 GRNVAC1 40 ascending dose 40 phase IIIb 40 albiglutide 40 Professor Francesco Muntoni 40 Dahej LNG terminal 40 Phase III randomized controlled 40 condensate stripping 40 Phase III randomized 40 mitogen activated ERK kinase 40 Microchip MPLAB 40 Tawke # 40 delta opioid receptor 40 Lil Sluggers 40 trial evaluating Prochymal 40 through GroupWeb EmailWire.Com 40 TKM Ebola 40 elotuzumab 40 prospective randomized multicenter 40 VITAL Trial 40 Hedgehog pathway inhibitor 40 methionine aminopeptidase 40 Lobito Tomboco 40 HDL Selective Delipidation 40 Fruit Tree Pruning 40 acyclovir Lauriad R 40 DSMB recommended 40 zileuton IV 40 MARVEL Trial 40 First Patient Dosed 40 Pinglu Project 40 Wideband Gapfiller Satellite 40 Kyzyloi Field 40 Investigational Device Exemption IDE 40 #kV substation 40 Sierra BioFuels 40 HPTN 40 REOLYSIN ® 40 NHDP phase 40 novel histone deacetylase 40 NEO3 40 Culmination 40 Phase IIb Trial 40 ISO IEC #:# CAN 40 Fx #A 40 Hedgehog antagonist 40 Orosi Mill Project 40 Pampalo Gold Mine 40 Xcellerated T Cells 40 MAGE A3 ASCI 40 exploratory Phase IIa 40 Allovectin 7 R 40 Morris J. Wosk 40 AzaSite Plus 40 TSX FAL.LV NYSE 40 GSK# [001] 40 PINKSHEETS NWMT PowerRating 40 phase III SIMPADICO 40 compound INCB# 40 Phase IIa clinical trials 40 masked placebo controlled 40 PTCOG 40 Rafael Urdaneta 40 Groundwork Hertfordshire 40 AIMM trial 40 GVAX R 40 Rigel R# 40 Urumalqui Project 40 POWERSTACK tm MC# 40 Phase 2a trial 40 Pivotal Study 40 Block IIA 40 scoping prefeasibility 40 Beike Holdings 40 lintuzumab SGN 40 demonstration SDD 40 PLK1 SNALP 40 fostamatinib 40 romidepsin novel 40 sequential dose escalation 40 Commence Phase 40 ATTRACT 40 Paschal Triduum 40 IMC A# 40 multicentre prospective 40 lorvotuzumab mertansine 40 generation URAT1 inhibitor 40 PIX# trial 40 SCAI Annual 40 Linnie Burton Jr. 40 MVax 40 Phase III clinical 40 tremelimumab 40 Keennon 40 TELCYTA 40 evaluating Xcytrin 40 Phase III ADT 40 LibiGel testosterone gel 40 Phase IIb trial 40 Bridging Generations 40 PF # [001] 40 Surfaxin LS 40 PEG Interferon lambda 40 Irma Graner testifying 40 Phase 2b Trial 40 RenalGuard System TM 40 Jubail Industrial City 40 opioid bowel dysfunction 40 Annamycin 40 Prefeasibility 39 drug conjugate 39 Eppley Auditorium 39 peginesatide 39 iNews Aggregator 39 #.#hrs CET 39 mertansine 39 prospective multicenter randomized 39 Microfocus APA 39 Phase 2b kidney transplant 39 StemEx 39 Magusi 39 oral prodrug 39 TACI Ig 39 CHS commons 39 IIIA NSCLC 39 randomized Phase IIb 39 subcutaneous PRO 39 SoftScan R 39 Pharmacokinetic Study 39 BR.# 39 Abong gold 39 investigational humanized monoclonal antibody 39 OLYMPIA registry 39 oral ridaforolimus 39 feasability study 39 Eds Major 39 ritonavir boosted danoprevir 39 Mesaieed Qatar 39 Amigal 39 Phase 1b dose escalation 39 PRISM reactor 39 GSF Development Driller 39 JunJing III 39 perifosine KRX 39 #Noon 39 Andy Schleck Giro 39 MINDSET 39 Midfield Terminal Complex 39 NHDP Phase 39 Keystone Pipeline System 39 Amirhossein Sairafi 39 Therapeutics TCT scientific 39 NJ1 39 initiate Phase 39 oral RELISTOR 39 Cadarache France 39 Frontier JetExpress operated 39 feasiblity study 39 Loramyc TM 39 securities issuable pursuant 39 Greater Angostura 39 minor leaguer Collin Cowgill 39 Qnexa TM 39 fidaxomicin Phase 39 Luminex xMAP R 39 multicentre 39 Dacogen injection 39 MOTIVATE 39 Palm Monorail 39 Taylor underwent tracheotomy 39 Panzem R NCD 39 www.systemc.org 39 Ras Abu Fontas 39 Organization IEEE ISTO 39 Mansker Farms 39 Clinical Trial Results 39 GPS IIIA 39 Tesetaxel 39 initiate Phase 2b 39 GroupWeb Emailwire.com 39 biliary tract cancer 39 4S eConnect 39 phase 2a 39 MinDOC 39 midstage clinical 39 Panzem ® 39 Alocrest 39 Association IPMA 39 AERAS-#/Crucell Ad# 39 vessel VSS Enterprise 39 Plein Air Competition 39 OvaRex R 39 RhuDex ® 39 Tolerability Study 39 ToxCast TM 39 Bankable Feasibility Study BFS 39 Protease Inhibitor 39 Beijing Guangzhou Shenzhen 39 Asbestos abatement 39 Melvin Jovel pleaded guilty 39 MW Teesta 39 http:/www.genta.com/investorrelation/events.html 39 Kogi Sokoto 39 PDE4 inhibitor 39 Lahaina Bypass 39 WriteByNight 39 Bassmaster Opens Women 39 Announces Upcoming Investor 39 SNUFFsurgeryNEWS Let us 39 AIR CF1 39 Réunion des Musées Nationaux 39 trastuzumab emtansine T DM1 39 Covalys 39 Selective Cardiac Myosin Activator 39 Dragon spacecraft 39 antibody MAb 39 Phase III Clinical Trials 39 SPIRIT FIRST 39 Bella Venezia 39 RPL refinery 39 horsepower Tor 39 #:# randomization 39 Rheology Solutions 39 PMSSY 39 Enzastaurin 39 candidate brentuximab vedotin 39 Zemplar Capsules 39 ABL inhibitor 39 Enhanze TM Technology 39 rPA anthrax vaccine 39 oral methylnaltrexone 39 Trofex 39 Suncor Firebag 39 Liraglutide Effect 39 STRIDE PD 39 REGEN trial 39 SparVax TM 39 gunman Giuseppe Zangara 39 RMEI works 39 phase IIb study 39 ACC5 Phase 39 MKC# 39 Tarvacin Anti Cancer 39 manufactures fluorescent lighting 39 Nasdaq HBE 39 big topsy turndown 39 ofatumumab 39 HuMax EGFr 39 Arahuay pilot 39 Clinical Study 39 AEHF satellite 39 ENGAGE AF TIMI 39 #km 2D seismic 39 Greek Orthodox Patriarch Theofilos 39 CholeraGarde R 39 IIa clinical trial 39 adjudicatory hearings 39 noncompetitive 5K 39 Universite Montpellier 39 artist residencies 39 dozen Coloramas 39 Androxal TM 39 Prodarsan 39 PEG PAL 39 TASKi3 39 MontaVista DevRocket 39 dyskinesia PD LID 39 phase IIb trial 38 predesign 38 midstage trials 38 pivotal Phase III 38 EOquin TM 38 Achieves Breakthrough 38 Fast Tracked Phase 38 EPC# 38 Krishnapatnam Andhra Pradesh 38 Bioral Amphotericin B 38 Design FEED 38 Allovectin 7 ® 38 Phase 2a Study 38 clinical trial 38 VirtualLogix VLX enables 38 Kemetco Research 38 torezolid phosphate 38 OvaRex ® MAb 38 lintuzumab 38 TransVax tm 38 estrogen receptor modulator 38 Hypoactive Sexual Desire Disorder 38 blind randomized placebo 38 Phase 2a Trial 38 #/#-ton girder began 38 microdosing studies 38 prefeasibility feasibility 38 subproject 38 Bruce Wrobel 38 Fujitsu datacenters 38 ADXS# 38 PINKSHEETS NMKT 38 EmbraceAC 38 CRLX# 38 Meets Primary Endpoint 38 CONSERV 38 aplindore 38 AACR #st Annual Meeting 38 Dyloject TM 38 celebrate Utami 38 evaluating RDEA# 38 Gradient Array 38 Red Cross Lifeguarding 38 ILUVIEN ® 38 tolerated dose MTD 38 Spectator gates 38 chemosaturation 38 TG MV 38 ToGA 38 Negligent homicide carries 38 Prodarsan ® 38 LCP AtorFen 38 Phase 2a preventative 38 ospemifene 38 stated Michelle Berrey 38 CORE Phase 38 dose escalation 38 Tom Bevill Lyceum 38 Mainstay Gallery 38 East Toba 38 nab paclitaxel 38 MEK inhibitor RDEA# 38 FDA Investigational Device 38 ENRGY 38 Vaxfectin R adjuvant 38 NOR Flash NAND Flash 38 leading oral taxane 38 sNDA submission 38 Pivotal Trials 38 BrachySil TM 38 PS# DARA 38 Genz # 38 Brimstone leach pad 38 Lu AA# 38 GPS IIIA satellite 38 PartSmart Web 38 Cervical Cancer Detection 38 Exhibitor Profiles 38 EMPOWER ™ 38 BENLYSTA ® 38 cetrorelix pamoate 38 multicenter clinical 38 Dextofisopam 38 TG# [001] 38 relapsing multiple sclerosis 38 SAR CORRE MENA 38 KRN# 38 preconstruction phase 38 MW Pragati 38 opioid induced bowel dysfunction 38 Eleventh Plan Period 38 FAC-P/PM